Vaxart settles proxy contest, will add independent director and form new board committees

Vaxart, Inc.

Stockholder group withdrew three director nominations for 2026 Annual Meeting and books-and-records demand.
Company will search within 90 days for a mutually agreed independent director to join the Board.
Board to form Stockholder Engagement and Clinical & Regulatory Affairs Committees; refresh committee chairs.
Company to adopt director stock ownership guidelines and a resignation policy for majority-vote failures.
Vaxart will reimburse stockholder group up to $650,000 for proxy contest expenses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.